Testing ersodetug for low blood sugar from neuroendocrine tumors
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new medicine called ersodetug in people whose neuroendocrine tumors cause dangerously low blood sugar that standard treatments can't control. If you need IV sugar or nutrition for at least a week, this trial may offer a new option to help manage your blood sugar.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and agree to join the study.
- You have a type of tumor called a neuroendocrine tumor that causes low blood sugar.
- Standard treatments for low blood sugar have not worked well enough, and you need IV sugar or nutrition for at least 7 days.
- You must not have an active infection like HIV, hepatitis B, or hepatitis C.
- You should not have tried other experimental drugs within the last 30 days (or 5 half-lives, whichever is longer) unless the study team approves.
- Your life expectancy due to the tumor must be longer than 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving low-dose chemotherapy while your blood sugar is low can help treat advanced solid tumors that have stopped responding to standard treatments. It aims to see if this approach is safe and effective.
This trial tests a medicine called TROP2-ADC, which targets a protein on cancer cells to kill them. It is for people with advanced high-grade neuroendocrine tumors that have not responded to standard treatments. The goal is to see if this drug can shrink tumors or slow their growth.
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
This trial uses a lab-grown model of your tumor (called an organoid) to test which drugs might work best for you. It is for people with advanced pancreatic neuroendocrine tumors who cannot have surgery.
This trial is testing an injectable medicine called octreotide for people with advanced neuroendocrine tumors of the digestive system or pancreas. It aims to see if the medicine can help control the tumor.
This study tests whether using a continuous glucose monitor (a small device that tracks blood sugar levels) can help manage high blood sugar in people newly diagnosed with glioblastoma, a type of brain cancer. It aims to see if this monitoring can improve overall health during treatment.
Hear when a new Tumor Hyperinsulinism (Tumor HI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.